Sibu Kuriakose in Rockwall, Texas

Home Texas Rockwall

Sibu Kuriakose has Physician Assistant as his primary medical specialty. Their primary office is: 3150 Horizon Rd in Rockwall, Texas. There is an additional office location, for a total of two, for Sibu Kuriakose that can be viewed further down.

They're a part of the: Wfo Group Llc medical group which has around 7 members. You can call their office at 469-698-1000 to schedule an appointment. They also accept the Medicare-approved amount as payment in full. They attended Sorry, his university is not listed and graduated in 2020 (around 4 years of experience). They are not listed as doing telehealth appointments, but this may have changed. It can't hurt to call and check. If anything it may encourage them to make them available if they are not currently.

Sibu Kuriakose Office Phone and Directions

Sibu Kuriakose
Wfo Group Llc
3150 Horizon Rd
Rockwall, Texas 75032
469-698-1000

Patient Ratings
Please rate your experience with Sibu Kuriakose below to help others make a more informed decision. Thanks!

Current Rating: Loading...

Phone: 469-698-1000

Enter a starting address:

Healthcare Info for Sibu Kuriakose

Medical School: Sorry, his university is not listed
Graduation Year: 2020
The Primary Medical Specialty for Sibu Kuriakose is listed as: Physician Assistant
Approximate Years of Experience: 4
PAC (PECOS ID)#: 5496159576
NPI #: 1336734409
NPI Created On: 03/01/2021
NPI Last Updated Listed as: 09/27/2022
Primary Taxonomy Code: 363A00000X
License Number:
PA14258
Listed Gender: Male

Open Payments Data. This can include items to test (Durable Medical Equipment (DME)), Biological, Drug Samples, etc. This data must be reported to CMS.

Payments Total: $108

Number of Payments:: 1

Form of Payment: In-kind items and services

Record ID:: 838488351

Being Disputed:: No

Product Related: Yes

Drug or Biological: Drug

Product Category #1: ANTILIPEMIC AGENTS

Name of Drug #1: NEXLIZET

Open Associated Drug #1: 72426-818-03

Drug or Biological: Drug

Product Category #2: ANTILIPEMIC AGENTS